Blueprint Medicines to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020
Blueprint Medicines Corporation (NASDAQ: BPMC) will host a live conference call and webcast on October 29, 2020 at 8:30 a.m. ET to discuss its third-quarter 2020 financial results and provide a corporate update. Investors can access the call by dialing (855) 728-4793 domestically or (503) 343-6666 internationally, using conference ID 2995408. A webcast will be available post-call on the Blueprint Medicines website. The company specializes in precision therapies targeting genomically defined cancers, rare diseases, and cancer immunotherapy.
- Company focuses on genomically defined cancers and rare diseases.
- Two approved precision therapies and multiple investigational medicines in development.
- None.
CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and provide a corporate update.
To access the live conference call, please dial (855) 728-4793 (domestic) or (503) 343-6666 (international), and refer to conference ID 2995408. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.
About Blueprint Medicines
Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We have two approved precision therapies and are currently advancing multiple investigational medicines in clinical development, along with a number of research programs. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-report-third-quarter-2020-financial-results-on-thursday-october-29-2020-301157665.html
SOURCE Blueprint Medicines Corporation
FAQ
When will Blueprint Medicines report its Q3 2020 financial results?
How can I access the Blueprint Medicines conference call?
What is the focus of Blueprint Medicines Corporation?
